Research programme: tubulin polymerisation inhibitors - Threshold Pharmaceuticals

Drug Profile

Research programme: tubulin polymerisation inhibitors - Threshold Pharmaceuticals

Alternative Names: TH-337; TH-482; TH-494

Latest Information Update: 19 Aug 2009

Price : $50

At a glance

  • Originator Threshold Pharmaceuticals
  • Class
  • Mechanism of Action Capillary permeability stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 09 May 2007 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top